GraceKa

Respiratory Trainee - interested in Immunology, Infectious Disease, Critical Care. Lover of festivals/music/art. ILD Fellow SCGH, Perth 2024 🇦🇺

[Star Wars Holocron @sw_holocron]

Thinking about this today

[M Raheel Khan @RKhanOnc]

This #Movember I am pleased to announce a major milestone towards our National Registry for #TesticularCancer #Survivors
#SLECT trial now approved by R&I in @stjamesdublin and @CancerInstIRE
Hoping to expand to other cancer centre in coming weeks

[James D Chalmers @ProfJDChalmers]

Approved today: the first ever approved therapy for bronchiectasis in Europe
Congratulations investigators, patients and Insmed
Science changes lives
European Commission Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union - Nov 18, 2025
https://t.co/8qP8JEYEXd

[David Juurlink @DavidJuurlink]

Now THAT is a prescribing cascade

@CarolynTanMD

[Allison Fitzgerald, MD, PhD @allisonoconn]

Today I learned that sometimes hepatocellular carcinoma can be diagnosed on imaging alone. If the patient has cirrhosis, chronic hep B or prior HCC an LI-RADS score of 5 is diagnostic! LI-RADS 4 requires biopsy and LI-RADS 3 or less is likely benign and can be monitored.

[Jostein Hauge @haugejostein]

A new paper published in The Lancet — one of the world's most respected health journals — finds that sanctions imposed by the West on developing countries have caused *38 million deaths* since 1971.

[GraceKa @GraceAlexK]

@JayanthKumarNa7 Looks like Middle Earth…

[Martin Picard @MitoPsychoBio]

Does mental stress affect our mitochondria?

In this new paper, we asked if 5 minutes of mental stress (public speaking) changed the amount of cell-free mitochondrial DNA (cf-mtDNA)

Absolute saliva cf-mtDNA levels increased on average by 280% after mental stress!

🧵

[GraceKa @GraceAlexK]

@mccarthymt7 There was a lot less interventions available 15 years ago.

[Mary Cushman 🫀🧠🩸 @MaryCushmanMD]

Is this the end of rivaroxaban for acute VTE?
@LanaCastellucci presenting the COBBRA trial - 1st RCT comparing apixaban to riva over 3 months.
56% reduction in bleeding risk with apixaban.
A safer Rx with the same efficacy.
#ISTH2025

[CHORUS Trial @ChorusTrial]

Great news! The CHORUS Trial is now open to recruitment, congratulations to @PilarRiveraOrt1 and her team for being the first site to open. @RoyalDevonNHS Excited to get started 🎉📷 @ActionPFcharity

[ERS publications @ERSpublications]

ERJOR: A walk test of 3 min still detects most desaturation events with equivalent prognostic value. Shorter walk tests could be used clinically, which would be a more efficient and patient-centred approach and also help the move towards remote monitoring. https://t.co/zBRYMe0cM3

[Ramy Sedhom, MD, FASCO @ramsedhom]

Today, I spoke @NorthwesternMed Grand Rounds on “The Price of Progress” - a reminder our excitement post-#ASCO25 should be tempered by reality:
🧾 33% of pts spend their life savings within 2 yrs of a cancer dx
🧠 50% experience financial distress
💼 75% leave the workforce

[Y C Gary Lee @YCGaryLee]

Find all TAPS (The Australasian Pleural Seminars): 15min @ on
https://t.co/G8ftVqdTkI

Or go straight to the latest from @e_fysh on Pleural Effusion in Intensive Care on
https://t.co/3CDOK4PYvD

Enjoy!

@PleuralPOCUS @UKPleura @ALATorax @aabip @tsanz_thoracic @TOGAANZ @APSRapsr @accpchest @NCARD_research @uwanews @PulmPEEPs @iPulmOG

[GraceKa @GraceAlexK]

Such an accurate statement!!

[Nick Mark MD @nickmmark]

Chronically renaming diseases is a great way for academics to feel important and for patients and most clinicians to feel confused.

[Naftali Kaminski @KaminskiMed]

Wow! What a day for #CureIPF & #ATS2025! First positive drug trial in 10 years in IPF!! Treatment with Nerandomilast -> ⬇️FVC decline compared to placebo in patients on antifibrotics or untreated. Kudos Drs Richeldi and Wijsenbeek and #FibroneerIPF team https://t.co/ZRw5qwTlPc

[ERS publications @ERSpublications]

Breathe: This review summarises interesting insights into interstitial lung disease pathogenesis from a translational science point of view @3Assembly @ERSpublications @EuroRespSoc @EarlyCareerERS @SaraOcana1 https://t.co/jw5HdhHOMJ

[Nick Hopkinson @COPDdoc]

Clinical Statement: Medical management of inpatients with tobacco dependency. @BTSrespiratory @ThoraxBMJ https://t.co/rgccFGRa2H @AshOrgUK @asthmalunguk

[ERS publications @ERSpublications]

ERJ: Pirfenidone does not significantly reduce the proportion of patients with post-COVID-19 fibrotic changes after 6 months of treatment. FVC % improvement and % HRCT fibrotic reduction with pirfenidone were not statistically different from placebo. https://t.co/AmGNYMaDsl

[Rohit Aggarwal @docrota]

Everyone in CTD-ILD world, please see this paper on Abatacept for the treatment of myositis-associated interstitial lung disease (ATtackMy-ILD), a RCT in IIM-ILD. Even though primary outcome was not met, but PFTs and HRCT trends before and after Abatacept are interesting and worth considering further larger study. Congratulations to Attack My ILD team and especially Nantakarn. https://t.co/09if0yCf7R